MORPHINE SULFATE INJECTION SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

MORPHINE SULFATE

Saatavilla:

JAMP PHARMA CORPORATION

ATC-koodi:

N02AA01

INN (Kansainvälinen yleisnimi):

MORPHINE

Annos:

10MG

Lääkemuoto:

SOLUTION

Koostumus:

MORPHINE SULFATE 10MG

Antoreitti:

INTRAMUSCULAR

Kpl paketissa:

15G/50G

Prescription tyyppi:

Narcotic (CDSA I)

Terapeuttinen alue:

OPIATE AGONISTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0104545001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2020-06-18

Valmisteyhteenveto

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
MORPHINE SULFATE INJECTION
Sterile Solution
2 mg/mL
,
10 mg/mL and 15 mg/mL
USP
Intravenous, Intramuscular, and Subcutaneous
Narcotic Analgesic
JAMP Pharma Corporation
Date of Preparation: June 17, 2020
1310 rue Nobel
Boucherville, Quebec,
Canada
J4B 5H3
Submission Control Number: 233783
_Morphine Sulfate Injection _
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
12
DRUG INTERACTIONS
.................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
15
OVERDOSAGE
................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 20
STORAGE AND STABILITY
.........................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 21
PART II: SCIENTIFIC INFORMATION 23
PHARMACEUTICAL INFORMATION
.........................................................................
23
REFERENCES
..................................................................................................................
24
PATIEN